BCYC — Bicycle Therapeutics Balance Sheet
0.000.00%
- $566.23m
- -$154.23m
- $35.28m
- 58
- 26
- 13
- 22
Annual balance sheet for Bicycle Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K | 
| Standards: | USG | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Short Term Investments | 136 | 439 | 339 | 526 | 880 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 14.6 | 11.9 | 21.2 | 24 | 35.7 | 
| Prepaid Expenses | |||||
| Total Current Assets | 156 | 459 | 369 | 562 | 929 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.61 | 17.8 | 32.8 | 27.7 | 17.2 | 
| Other Long Term Assets | |||||
| Total Assets | 161 | 480 | 411 | 595 | 957 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 23.1 | 36.2 | 53.3 | 69.5 | 67.2 | 
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 65.7 | 134 | 140 | 224 | 164 | 
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 95.5 | 346 | 271 | 371 | 793 | 
| Total Liabilities & Shareholders' Equity | 161 | 480 | 411 | 595 | 957 | 
| Total Common Shares Outstanding |